Discover Ono Pharmaceutical's groundbreaking patent for autophagy-inhibiting compounds, targeting various cancers with innovative MEK inhibitors like selumetinib.
Changes clinical practice: The risks and benefits of adjuvant aromatase inhibitors (AIs) should be weighed carefully, especially in postmenopausal women with early-stage, hormone-receptor positive ...
Citation: PARP1 selective inhibitor yields potent and durable antitumor activity in patient-derived preclinical models (2024, September 3) retrieved 23 September 2024 from https://medicalxpress ...
Ruscetti's previous research demonstrated that two cancer drugs (MEK inhibitor trametinib and CDK4/6 inhibitor palbociclib, or T/P) can promote blood vessel development, enabling greater T cell ...
The approval of the BRAF–MEK duo was based on results of the phase II PHAROS trial, which assessed its efficacy and safety in both newly diagnosed and previously treated patients with metastatic NSCLC ...